News

Expert Valuation Insights: Nvidia and Tesla in Question

Expert Valuation Insights: Nvidia and Tesla in Question

Understanding High Valuations of Tech Giants

Aswath Damodaran, a renowned finance professor at NYU Stern and often called the "Dean of Valuation," has raised concerns regarding the valuations of significant technology firms. His criticism especially targets Nvidia Corp. (NASDAQ: NVDA) and Tesla Inc. (NASDAQ: TSLA), labeling them as the most irrationally priced companies on the current market.

Nvidia: A Questionable Valuation

In a recent discussion on the Prof G Markets podcast, Damodaran shared his skepticism regarding the evaluation of Nvidia, which has remarkably pushed its market capitalization to staggering heights, particularly in the AI space. He indicated that the projections supporting Nvidia’s high stock price do not appear to be grounded in realistic expectations.

“The assumptions behind Nvidia's valuation suggest it is the greatest company ever, projecting 80% gross margins indefinitely, with revenues soaring to a trillion dollars or more,” he noted. However, he emphasized that such predictions are unsubstantiated and fail to withstand logical analysis.

Tesla's Valuation Conundrum

Damodaran placed Tesla in a similar category of irrationality, citing distinct reasons. While he perceives Nvidia's issues stem from unrealistic mathematical projections, he argues that Tesla suffers from a lack of coherence regarding its future direction. “I'm not even sure what Tesla is as a company anymore,” he remarked, expressing doubt about the company's narrative going forward.

Market Outlook: Risks for Big Tech

Damodaran's pessimistic viewpoint does not end with these two companies. He extended his caution to cover the larger tech cohort, particularly the Magnificent 10, which represents a significant portion of the S&P 500’s market capitalization. He cautioned that a correction affecting these trade leaders would likely lead to broader market consequences, adversely impacting index funds and passive investors across the board.

Identifying Less Overvalued Stocks

Despite his critical commentary on some major tech players, Damodaran pointed out Alphabet Inc. (NASDAQ: GOOG, GOOGL) and Amazon.com Inc. (NASDAQ: AMZN) as among the least overvalued. He noted their clearer pathways to efficiency and profitability, which do not solely hinge on the AI narrative that other tech firms depend upon so heavily.

In a notable shift, Damodaran declared that for the first time in his investing career, he is reallocating parts of his portfolio into cash, contemplating collectibles. He acknowledged this move as drastic for a seasoned value investor, particularly in light of the pervasive overvaluation in the tech sector. “It’d be difficult to find one that’s undervalued,” Damodaran stated, reflecting the challenging landscape for tech investments.

Recent Performance of Nvidia and Tesla

In recent trading sessions, Tesla saw a minor decline, trading 0.38% lower after a session that closed at $408.92, reflecting a year-to-date rise of 7.81% and 20.72% over the year. On the other hand, Nvidia faced a decline of 1.88%, closing at $186.60, with a year-to-date growth of 34.91%.

Both companies seem to be experiencing shaky trends. For Tesla, while it maintains a stronger price trend over medium and long durations, it witnesses short-term performance struggles, showing a poor ranking in value. Similarly, Nvidia showcases a better medium-term performance while facing shortcomings in the short term.

Frequently Asked Questions

What are Aswath Damodaran's main concerns about Nvidia?

He questions the unrealistic projections for Nvidia's growth and profitability that fail to hold up under scrutiny.

How does Damodaran view Tesla's business model?

He expresses confusion regarding Tesla's narrative, stating it's unclear what direction the company is heading.

What does Damodaran predict for the broader tech market?

He believes that a downturn in key tech stocks could significantly impact the overall market and passive investment strategies.

Which companies does Damodaran consider less overvalued?

Alphabet Inc. and Amazon.com Inc. are identified as less overvalued, with clearer profit paths.

What investment strategy is Damodaran adopting now?

He is moving portions of his portfolio into cash and is considering collectibles, a major shift for a traditional value investor.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Updated Category News Views 295

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

Continue Reading
ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 143

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 132

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 143

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
Bio-Thera's New Data: A Game Changer for NSCLC?

Updated Category News Views 214

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 160

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 185

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
Alaska's Insurance Maze: Coverage Over Cheap Policies

Updated Category News Views 70

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Continue Reading
Axon Body 5: A Leap Forward in AI for Public Safety

Updated Category News Views 270

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Continue Reading
Apalutamide Boosts Outlook for Prostate Cancer Treatment

Updated Category News Views 69

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Continue Reading

Top 5 Most Recently Viewed Articles

Oral Semaglutide Curbs Heavy Drinking: CU Study Insights

Updated Category News Views 12

New Frontiers in Tackling Alcohol Use Disorder Diabetes meds aren't just boxing in sugar levels; they're taking swings at alcohol cravings, too. The University of Colorado Anschutz threw their hat in the ring with a study that put oral semaglutide—usually in the diabetes and weight loss circuit—to a different test. Turns out, it's packing a punch against heavy...

Continue Reading
Julie Van Kleeck Strengthens Leadership at Paragon Space

Updated Category News Views 121

Julie Van Kleeck Joins Paragon Space Development Corporation Board Paragon Space Development Corporation (Paragon) proudly announces the appointment of Julie Van Kleeck to its Board of Directors. With a remarkable background in the space technology sector, Julie is set to enhance Paragon's mission with her extensive market insights and solid operational experience. Rich...

Continue Reading
Exploring Advanced Techniques for Fracture Healing in Orthopaedics

Updated Category News Views 302

Micromotion Nailing for Enhanced Fracture Healing OrthoXel is thrilled to announce an important presentation by Dr. Hannah Dailey, Co-Founder and Chief Scientific Officer, focusing on the innovative technique of micromotion nailing aimed at accelerating fracture healing. This presentation will be highlighted at an esteemed meeting gathering leading experts in the field of...

Continue Reading
Resilient Job Market Gains Amid Signs of Slowing Growth Ahead

Updated Category News Views 191

Overview of Recent Labor Market Trends The US economy has shown unexpected strength, adding more jobs than anticipated recently, instilling fresh optimism regarding the labor market's near-term stability. With political changes on the horizon, the economy's performance under the new administration remains a topic of interest. Nonetheless, we can assert that the incoming...

Continue Reading
MD Hyperbaric Expands Presence in Key U.S. Markets

Updated Category News Views 6

Expanding the Oxygen Therapy Frontier When you're talking about healing that's both ancient and cutting-edge, hyperbaric oxygen therapy (HBOT) kind of steals the show. MD Hyperbaric, calling the shots since 2021, is breaking new ground in San Antonio, Las Vegas, and Rochester. Why This Matters HBOT isn't just another fancy healthcare fad. We're seeing a real push toward...

Continue Reading